UCLA Researchers & Innovators
Industry & Investors
News & Events
About
Concierge
Search Results - glioma
3
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Interferon Activation Score Is a Biomarker for Immunotherapy in Malignant
Glioma
Patients (UCLA Case No. 2024-043)
UCLA researchers from the Department of Neurosurgery have characterized immune responses in malignant
glioma
patients receiving immunotherapy to develop a robust biomarker that will allow prediction of clinical outcomes following treatment. BACKGROUND: Malignant gliomas are the most common primary brain tumors in adults. No cures exist and most gliomas...
Published: 10/23/2024
|
Inventor(s):
Robert Prins
Keywords(s):
adjuvant therapy
,
Biomarker
,
Chemotherapy
,
Clinical Trial
,
dendritic cell vaccination
,
Glioblastoma
,
Glioma
,
immune response
,
Immunotherapy
,
interferon
,
malignant
glioma
Category(s):
Diagnostic Markers > Immunology
,
Diagnostic Markers > Cancer
,
Therapeutics > Inflammation And Inflammatory Diseases
,
Therapeutics > Oncology
,
Therapeutics > CNS and Neurology
Compounds and Methods for Treating Cancer by Destroying Cancer Stem Cells (UCLA Case No. 2021-286)
Researchers from UCLA’s Department of Chemistry and Biochemistry and the Department of Radiation Oncology have synthesized a set of compounds for the eradication of cancer stem cells. These compounds are predicted to cross the blood brain barrier and show promise as effective interventions for glioblastoma in both in vitro and in vivo assays. BACKGROUND:...
Published: 7/11/2024
|
Inventor(s):
Michael Jung
,
Frank Pajonk
Keywords(s):
blood-brain barrier
,
Brain
,
Cancer
,
Cancer stem cells
,
drug screening
,
GBM
,
Glioblastoma
,
Glioma
,
new chemical entity
Category(s):
Therapeutics > Oncology
,
Therapeutics > CNS and Neurology
,
Therapeutics > Stem Cells And Regenerative Medicine
Targeted Epigenetic Editing as Novel Therapy for Malignant
Glioma
(UCLA Case No. 2023-047)
UCLA Researchers in the Department of Neurology/Neuro-Oncology and the David Geffen School of Medicine have developed methods for the Cas9-CRISPR mediated epigenetic targeting of malignant
glioma
, and which results in enhanced chemosensitivity to standard chemotherapeutic agents. BACKGROUND: Malignant gliomas are aggressive brain tumors originating...
Published: 1/17/2024
|
Inventor(s):
Serendipity Zapanta Rinonos
,
Albert Lai
Keywords(s):
Brain
,
Cancer
,
Cancer stem cells
,
Chemotherapy
,
Combination therapy
,
CRISPR
,
CRISPR-Cas9
,
Epigenetics
,
GBM
,
Glioma
Category(s):
Therapeutics > Oncology
,
Therapeutics > CNS and Neurology